HC Wainwright reaffirmed their buy rating on shares of Lexicon Pharmaceuticals (NASDAQ:LXRX - Free Report) in a report published on Wednesday morning,Benzinga reports. The firm currently has a $4.00 price objective on the biopharmaceutical company's stock.
LXRX has been the topic of a number of other reports. Needham & Company LLC reissued a "hold" rating on shares of Lexicon Pharmaceuticals in a report on Monday, December 23rd. Leerink Partners set a $6.00 target price on shares of Lexicon Pharmaceuticals and gave the stock an "outperform" rating in a research report on Friday, October 18th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat, Lexicon Pharmaceuticals currently has an average rating of "Hold" and an average target price of $5.00.
Check Out Our Latest Research Report on Lexicon Pharmaceuticals
Lexicon Pharmaceuticals Price Performance
Shares of LXRX stock traded down $0.06 on Wednesday, hitting $0.76. 4,049,932 shares of the stock traded hands, compared to its average volume of 5,387,939. The company has a debt-to-equity ratio of 0.56, a current ratio of 7.45 and a quick ratio of 7.43. Lexicon Pharmaceuticals has a 52 week low of $0.62 and a 52 week high of $3.73. The firm has a 50 day simple moving average of $0.78 and a two-hundred day simple moving average of $1.36. The firm has a market cap of $186.21 million, a price-to-earnings ratio of -1.01 and a beta of 1.06.
Lexicon Pharmaceuticals (NASDAQ:LXRX - Get Free Report) last posted its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.18) EPS for the quarter, missing analysts' consensus estimates of ($0.17) by ($0.01). The business had revenue of $1.75 million for the quarter, compared to the consensus estimate of $3.14 million. Lexicon Pharmaceuticals had a negative net margin of 4,109.41% and a negative return on equity of 107.38%. During the same period in the prior year, the business earned ($0.21) earnings per share. As a group, equities research analysts predict that Lexicon Pharmaceuticals will post -0.66 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Lexicon Pharmaceuticals
Several institutional investors have recently added to or reduced their stakes in the company. FMR LLC grew its holdings in shares of Lexicon Pharmaceuticals by 28.9% in the third quarter. FMR LLC now owns 49,867,042 shares of the biopharmaceutical company's stock valued at $78,291,000 after purchasing an additional 11,179,919 shares in the last quarter. Point72 Asset Management L.P. lifted its position in Lexicon Pharmaceuticals by 605.2% during the second quarter. Point72 Asset Management L.P. now owns 4,121,191 shares of the biopharmaceutical company's stock valued at $6,924,000 after purchasing an additional 3,536,805 shares during the last quarter. Marshall Wace LLP grew its stake in shares of Lexicon Pharmaceuticals by 138.5% in the 2nd quarter. Marshall Wace LLP now owns 1,190,448 shares of the biopharmaceutical company's stock worth $2,000,000 after buying an additional 691,276 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of Lexicon Pharmaceuticals by 8.4% in the 3rd quarter. Geode Capital Management LLC now owns 3,523,971 shares of the biopharmaceutical company's stock worth $5,534,000 after buying an additional 273,436 shares during the last quarter. Finally, BBR Partners LLC increased its holdings in shares of Lexicon Pharmaceuticals by 74.1% in the 3rd quarter. BBR Partners LLC now owns 470,000 shares of the biopharmaceutical company's stock worth $738,000 after buying an additional 200,000 shares during the last quarter. Hedge funds and other institutional investors own 74.70% of the company's stock.
About Lexicon Pharmaceuticals
(
Get Free Report)
Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.
See Also
Before you consider Lexicon Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lexicon Pharmaceuticals wasn't on the list.
While Lexicon Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
